NEXT-GENERATION DRUG DEVELOPMENT: RISKY AND COSTLY, BUT WORTH IT
Generic drugs, which drive a $40 billion dollar generics industry expected to
hit $60 billion by 2007, account for 53% of all prescriptions filled in the United
States today. According to a new report from pharmaceutical research firm Cutting Edge Information,
brand name companies have turned to the risky business of next- generation drug
development to protect revenues from generic competitors.
Armenian Medical Network